Navigation Links
Influenza Vaccines Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Date:10/17/2011

NEW YORK, Oct. 17, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Influenza Vaccines Therapeutics - Pipeline Assessment and Market Forecasts to 2018

http://www.reportlinker.com/p0656883/Influenza-Vaccines-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Influenza Vaccines Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, "Influenza Vaccines Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global influenza vaccines market. The report identifies the key trends shaping and driving the global influenza vaccines market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global influenza vaccines sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData estimates that the global influenza vaccines vaccines market was valued at $3,525.1m in 2011, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 5.8% over the next seven years, to reach $5,242.9m in 2018. The moderate growth of the market is due to the increasing awareness among people about the importance of vaccination against influenza vaccines, and the approval of new influenza vaccines vaccines. The universal immunization recommendation by the Advisory Committee on Immunization Practices (ACIP) and several government awareness vaccination programs would help to increase the vaccination coverage for influenza vaccines. The upcoming influenza vaccines vaccines include seasonal vaccines such as FluBlok and MEDI-3250, pandemic and pre-pandemic (mainly H5N1) vaccines such as Flu (Pre) Pandemic Vaccine, H5N1 pandemic influenza vaccines vaccine and Vepacel, and universal influenza vaccines vaccines such as BVX-M001, MVA-NP+M1, Flu-v and others. The influenza vaccines vaccines market is also set to witness the launch of quadrivalent vaccines such as Fluzone QIV, and adjuvant vaccines such as JVRS-100 with Fluzone and IC31 Seasonal influenza vaccines Vaccine. The pipeline also includes vaccines with different routes of administration, such as oral vaccine (Avian influenza vaccines (H5N1) Oral Vaccine), nasal vaccine (influenza vaccines Intranasal Vaccine), vaccine in the form of nasal dry powder (GelVac), and vaccine patch (Pandemic influenza vaccines Vaccine Patch).

Scope

The report provides information on the key drivers and challenges of the influenza vaccines market. Its scope includes -

- Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) influenza vaccines market revenues data from 2005 to 2010, forecast for eight years to 2018.

- Pipeline analysis data providing a split across the different phases, type of vaccines being developed and emerging trends by seven key markets. Pipeline candidates fall under major classes such as conjugate vaccine, combinational vaccine, polysachharide vaccines and others.

- Analysis of the current and future competition in the seven key countries influenza vaccines market. Key market players covered are Novartis AG, GlaxoSmithKline, Sanofi, Pfizer Inc, LG Life Sciences, Sinovac Biotech and Eurocrine Vaccines.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the influenza vaccines therapeutics market.

- Analysis of key recent licensing and partnership agreements in influenza vaccines market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global influenza vaccines market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global influenza vaccines market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What is the next big thing in the global influenza vaccines market landscape? – Identify, understand and capitalize.

1 Table of Contents

1 Table of Contents 3

1.1 List of Tables 5

1.2 List of Figures 6

2 Influenza Vaccines - Introduction 7

2.1 Disease Overview 7

2.2 Epidemiology 8

2.3 Etiology and Pathophysiology 8

2.3.1 Types of Influenza Virus 8

2.3.2 Source of Influenza Virus 9

2.3.3 Drifting and Shifting of Influenza Virus 9

2.4 Signs and Symptoms 11

2.5 Diagnosis 11

2.6 Treatment and Management Options 13

2.7 GlobalData Pipeline Report Guidance 14

3 Influenza Vaccines: Market Characterization 15

3.1 Influenza Vaccines Market Size (2005-2010) – Global 15

3.2 Influenza Vaccines Market Forecast (2011-2018) – Global 16

3.3 Influenza Vaccines Market Size (2005-2010) – The US 17

3.4 Influenza Vaccines Market Forecast (2011-2018) – The US 18

3.5 Influenza Vaccines Market Size (2005-2010) – France 19

3.6 Influenza Vaccines Market Forecast (2011-2018) – France 20

3.7 Influenza Vaccines Market Size (2005-2010) – Germany 21

3.8 Influenza Vaccines Market Forecast (2011-2018) – Germany 22

3.9 Influenza Vaccines Market Size (2005-2010) – Italy 23

3.10 Influenza Vaccines Market Forecast (2011-2018) – Italy 24

3.11 Influenza Vaccines Market Size (2005-2010) – Spain 25

3.12 Influenza Vaccines Market Forecast (2011-2018) – Spain 26

3.13 Influenza Vaccines Market Size (2005-2010) – The UK 27

3.14 Influenza Vaccines Market Forecast (2011-2018) – The UK 28

3.15 Influenza Vaccines Market Size (2005-2010) – Japan 29

3.16 Influenza Vaccines Market Forecast (2011-2018) – Japan 30

3.17 Drivers and Barriers for the Influenza Vaccines Market 31

3.17.1 Drivers for the Influenza Vaccines Market 31

3.17.2 Barriers for the Influenza Vaccines Market 32

3.18 Opportunity and Unmet Need Analysis 33

3.19 Key Takeaway 34

4 Influenza Vaccines: Competitive Assessment 35

4.1 Overview 35

4.2 5.1.1 Strategic Competitor Assessment 35

4.3 Product Profiles for the Major Marketed Products in the Influenza Vaccines Market 36

4.3.1 Fluarix 36

4.3.2 FluLaval 37

4.3.3 Flumist 38

4.3.4 Fluvirin 39

4.3.5 Fluzone 39

4.4 Key Takeaway 40

5 Influenza Vaccines - Pipeline Assessment 41

5.1 Overview 41

5.2 Strategic Pipeline Assessment 41

5.2.1 Influenza Vaccines Pipeline – Pipeline by Phases of Development 42

5.2.2 Influenza Vaccines – Regulatory Filed Products 42

5.2.3 Influenza Vaccines – Phase III Pipeline 43

5.2.4 Influenza Vaccines – Phase II Pipeline 43

5.2.5 Influenza Vaccines – Phase I Pipeline 44

5.2.6 Influenza Vaccines – Pre-Clinical Pipeline 45

5.2.7 Influenza Vaccines – Discovery Pipeline 46

5.2.8 Technology Trends Analytical Framework 47

5.3 Influenza Vaccines – Clinical Pipeline by Types of Vaccine 49

5.4 Influenza Vaccines – Promising Drugs Under Clinical Development 49

5.5 Molecule Profile for Promising Drugs Under Clinical Development 50

5.5.1 FluBlok 50

5.5.2 Flu Vaccine 51

5.5.3 MEDI 3250 51

5.5.4 A-04-01D Vaccine 52

5.5.5 H5N1 Pandemic Influenza Vaccine 52

5.5.6 Vepacel 52

5.6 Key Takeaway 52

6 Influenza Vaccines: Clinical Trials Mapping 53

6.1 Clinical Trials by Region/Country (The US, EU5 and Japan) 53

6.2 Clinical Trials by Phase 54

6.3 Clinical Trials by Trial Status 55

6.4 Prominent Sponsors 56

6.5 Top Companies Participating in Influenza Vaccines Clinical Trials 58

7 Influenza Vaccines: Strategic Assessment 59

7.1 Key Events Impacting the Future Market 59

7.2 Influenza Vaccines: Implications for Future Market Competition 60

8 Influenza Vaccines: Future Players 61

8.1 Introduction 61

8.2 Company Profiles 62

8.2.1 AstraZeneca PLC 62

8.2.2 GlaxoSmithKline plc 63

8.2.3 Novartis AG 65

8.2.4 Baxter International Inc. 66

9 Influenza Vaccines: Licensing and Partnership Deals 68

10 Influenza Vaccines: Appendix 83

10.1 Market Definitions 83

10.2 Abbreviations 83

10.3 Methodology 85

10.3.1 Coverage 85

10.3.2 Secondary Research 86

10.3.3 Forecasting 86

10.3.4 Primary Research 88

10.3.5 Expert Panel Validation 89

10.4 Contact Us 89

10.5 Disclaimer 89

10.6 Bibliography 89

List of Tables

Table 1: Influenza Vaccines Market, Global, Revenue ($m), 2005–2010 15

Table 2: Influenza Vaccines Market, Global, Forecast ($m), 2011–2018 16

Table 3: Influenza Vaccines Market, The US, Revenue ($m), 2005–2010 17

Table 4: Influenza Vaccines Market, The US, Forecasts ($m), 2011–2018 18

Table 5: Influenza Vaccines Market, France, Revenue ($m), 2005–2010 19

Table 6: Influenza Vaccines Market, France, Forecasts ($m), 2011–2018 20

Table 7: Influenza Vaccines Market, Germany, Revenue ($m), 2005–2010 21

Table 8: Influenza Vaccines Market, Germany, Forecasts ($m), 2011–2018 22

Table 9: Influenza Vaccines Market, Italy, Revenue ($m), 2005–2010 23

Table 10: Influenza Vaccines Market, Italy, Forecasts ($m), 2011–2018 24

Table 11: Influenza Vaccines Market, Spain, Revenue ($m), 2005–2010 25

Table 12: Influenza Vaccines Market, Spain, Forecasts ($m), 2011–2018 26

Table 13: Influenza Vaccines Market, The UK, Revenue ($m), 2005–2010 27

Table 14: Influenza Vaccines Market, The UK, Forecasts ($m), 2011–2018 28

Table 15: Influenza Vaccines Market, Japan, Revenue ($m), 2005–2010 29

Table 16: Influenza Vaccines Market, Japan, Forecasts ($m), 2011–2018 30

Table 17: Influenza Vaccines – Regulatory Filed Products, 2011 42

Table 18: Influenza Vaccines – Phase III Pipeline, 2011 43

Table 19: Influenza Vaccines – Phase II Pipeline, 2011 43

Table 20: Influenza Vaccines – Phase I Pipeline, 2011 44

Table 21: Influenza Vaccines – Pre-Clinical Pipeline, 2011 45

Table 22: Influenza Vaccines – Discovery Pipeline, 2011 46

Table 23: Influenza Vaccines – Most Promising Drugs Under Clinical Development, 2011 49

Table 24: Influenza Vaccines – Clinical Trials by Country, 2011 53

Table 25: Influenza Vaccines – Clinical Trials by Phase, 2011 54

Table 26: Influenza Vaccines – Clinical Trials by Status, 2011 55

Table 27: Influenza Vaccines – Overall Sponsors, 2011 56

Table 28: Influenza Vaccines – Prominent Sponsors, 2011 57

Table 29: Influenza Vaccines – Top Companies Participating in Clinical Trials, 2011 58

Table 30: Astrazeneca - Influenza Pipeline Products, 2011 63

Table 31: GlaxoSmithKline - Influenza Pipeline Products, 2011 65

Table 32: Novartis AG - Influenza Pipeline Products, 2011 66

Table 33: Baxter International - Influenza Pipeline Products, 2011 67

Table 34: Influenza Vaccines: Licensing and Partnership Deals, 2011 68

List of Figures

Figure 1: Comparison of Seasonal and Pandemic Influenza 7

Figure 2: Comparison of Influenza A, B and C 9

Figure 3: Comparison of Influenza and the Common Cold 11

Figure 4: Influenza Virus Testing Methods 12

Figure 5: Clinical Algorithm for Consideration in the Assessment of Persons with Mild or Uncomplicated Influenza Illness 13

Figure 6: Influenza Vaccines Market, Global, Revenue ($m), 2005–2010 15

Figure 7: Influenza Vaccines Market, Global, Forecast ($m), 2011–2018 16

Figure 8: Influenza Vaccines Market, The US, Revenue ($m), 2005–2010 17

Figure 9: Influenza Vaccines Market, The US, Forecast ($m), 2011–2018 18

Figure 10: Influenza Vaccines Market, France, Revenue ($m), 2005–2010 19

Figure 11: Influenza Vaccines Market, France, Forecast ($m), 2011–2018 20

Figure 12: Influenza Vaccines Market, Germany, Revenue ($m), 2005–2010 21

Figure 13: Influenza Vaccines Market, Germany, Forecast ($m), 2011–2018 22

Figure 14: Influenza Vaccines Market, Italy, Revenue ($m), 2005–2010 23

Figure 15: Influenza Vaccines Market, Italy, Forecast ($m), 2011–2018 24

Figure 16: Influenza Vaccines Market, Spain, Revenue ($m), 2005–2010 25

Figure 17: Influenza Vaccines Market, Spain, Forecast ($m), 2011–2018 26

Figure 18: Influenza Vaccines Market, The UK, Revenue ($m), 2005–2010 27

Figure 19: Influenza Vaccines Market, The UK, Forecast ($m), 2011–2018 28

Figure 20: Influenza Vaccines Market, Japan, Revenue ($m), 2005–2010 29

Figure 21: Influenza Vaccines Market, Japan, Forecast ($m), 2011–2018 30

Figure 22: Opportunity and Unmet Need in the Influenza Vaccines Market 33

Figure 23: Influenza Vaccines – Strategic Competitor Assessment, 2010 36

Figure 24: Influenza Vaccines – Pipeline by Phase of Development, 2011 42

Figure 25: Influenza Vaccines – Technology Trends Analytics Framework, 2011 47

Figure 26: Influenza Vaccines – Technology Trends Analytics Framework – Description, 2011 48

Figure 27: Influenza Vaccines – Pipeline by Types of Vaccines, 2011 49

Figure 28: Influenza Vaccines – Clinical Trials by Country, 2011 53

Figure 29: Influenza Vaccines – Clinical Trials by Phase, 2011 54

Figure 30: Influenza Vaccines – Clinical Trials by Status, 2011 55

Figure 31: Influenza Vaccines – Overall Sponsors, 2011 56

Figure 32: Influenza Vaccines – Prominent Sponsors, 2011 57

Figure 33: Influenza Vaccines – Top Companies Participating in Clinical Trials, 2011 58

Figure 34: Influenza Vaccines Market, Drivers and Barriers, 2011 59

Figure 35: Implications for Future Market Competition in the Influenza Vaccines Market, 2011 60

Figure 36: Influenza Vaccines Market – Pipeline by Company, 2011 61

Figure 37: GlobalData Market Forecasting Model 88

Companies Mentioned

AstraZeneca PLC

GlaxoSmithKline plc

Novartis AG

Baxter International Inc.

To order this report:

Drug and Medication Industry: Influenza Vaccines Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Drug and Medication Business News

More  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. GSK Begins Shipments of Fluarix(R) and FluLaval(R) to U.S. Customers for 2008-2009 Influenza Season
2. Canopus Biopharma and Leading Chinese Researcher Team Up to Treat Avian Influenza, to Prevent Possible Pandemic
3. Sinovac Launches Seasonal Influenza Vaccine Anflu(R) for 2008-2009 Flu Season
4. Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate
5. Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
6. Vical and AnGes MG Sign Letter of Intent for Pandemic Influenza Program
7. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
8. Peramivir Phase 2 Data for the Treatment of Outpatient Influenza to be Presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
9. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
10. A New Way to Predict Outbreaks: Replikin Peptide Concentration in H5N1 Influenza Virus Genome as a Marker for Lethal Outbreaks
11. Lentigen Corporation and PATH Announce Partnership on Innovative Vaccine for Pandemic Influenza
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 11, 2016  Dovetail Genomics™ LLC today announced that ... for a planned metagenomic genome assembly service. Richard ... genome assembly method in a talk on Friday, February ... Technology conference in Orlando, Fla. ... datasets is difficult. Using its proprietary Chicago ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... cell treatment clinic in Quito, Ecuador. The new facility will provide advanced protocols ... patients from around the world. , The new GSCG clinic is headed ...
(Date:2/10/2016)... ASAE is introducing a hybrid membership model which will ... of joining or renewing through an organizational purchasing model. ... every employee in any size association or AMC office ... member benefits.   John H. Graham, IV ... allow organizations of any size and their employees to ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... three states, announced today the promotion of two long-standing principal investigators (PI) to ... Family Medicine, Clinical Research and Development. , Dr. Laurence Chu, a Benchmark Research ...
Breaking Biology Technology:
(Date:1/27/2016)... , Jan. 27, 2016  Rite Track, Inc. ... in West Chester, Ohio announced ... winning service staff, based in Austin, Texas ... and ability to provide modifications, installations and technical support ... , CEO of PLUS, commented, "PLUS has provided world ...
(Date:1/22/2016)... , Jan. 22, 2016 ... addition of the "Global Biometrics Market ... their offering. --> http://www.researchandmarkets.com/research/p74whf/global_biometrics ... "Global Biometrics Market in Retail Sector ... --> Research and Markets ( ...
(Date:1/20/2016)... Jan. 20, 2016  Synaptics Incorporated (NASDAQ: ... solutions, today announced sampling of S1423, its newest ... and small screen applications including smartwatches, fitness trackers, ... round and rectangular shapes, as well as thick ... with moisture on screen, while wearing gloves, and ...
Breaking Biology News(10 mins):